Related Experiment Video

Updated: Aug 14, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

Inhibitors of ABCG2-mediated multidrug resistance: Lead generation through computer-aided drug design

Laura Goracci1, Alessandra Nurisso2, Emile Roussel3

  • 1Department of Chemistry, Biology and Biotechnology, University of Perugia, Italy.

European Journal of Medicinal Chemistry
|January 11, 2023
PubMed

Insights

Researchers designed novel breast cancer resistance protein (BCRP) inhibitors using computer-aided drug design. These inhibitors show high potential in overcoming chemotherapy resistance in cancer cells.

Area of Science:

  • Pharmacology
  • Biochemistry
  • Computational Chemistry

Background:

  • Human breast cancer resistance protein (BCRP), also known as ABCG2, is a key transporter involved in multidrug resistance (MDR) in cancer cells.
  • Cancer cells utilize BCRP to develop resistance against various anticancer drugs, limiting treatment efficacy.
  • Developing effective BCRP inhibitors is a crucial strategy to enhance chemotherapy outcomes.

Purpose of the Study:

  • To design novel and effective inhibitors of breast cancer resistance protein (BCRP/ABCG2).
  • To elucidate the pharmacophoric features of BCRP binding sites using computational methods.
  • To guide the development of agents that can overcome chemotherapy resistance.

Main Methods:

  • Utilized computer-aided drug design (CADD) approaches.
  • Employed the FLAPpharm method to analyze pharmacophoric features of BCRP binding sites.
  • Designed and synthesized novel compounds based on computational predictions.

Main Results:

  • Successfully elucidated pharmacophoric features of a BCRP binding site regulating ATPase activity.
  • Identified three novel compounds exhibiting high inhibitory activity against BCRP.
  • Achieved nanomolar inhibitory activity with the most potent compound, demonstrating significant efficacy.

Conclusions:

  • Computer-aided drug design is an effective strategy for developing potent BCRP inhibitors.
  • The identified inhibitors hold promise for enhancing chemotherapy efficacy by overcoming BCRP-mediated drug resistance.
  • Further development of these inhibitors could lead to improved cancer treatment strategies.
Keywords:
ABCG2BCRPChromonesIndenoindolesLigand-based drug designMultiple drug resistancePharmacophore

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

1.4K
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

2.9K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
850
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
490
ABC Transporters: Exporter01:31

ABC Transporters: Exporter

ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
4.5K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K